Comparative study of autonomic dysfunction between Parkinson’s disease with LRRK2, PRKN, and GBA mutations
These findings that genetic background may influence the severity of autonomic dysfunction in PD. In particular, patients with <i>GBA</i> mutations appear to experience a greater autonomic symptom burden, underscoring the need for personalized clinical monitoring and further research into genotype-specific disease progression. However, inconsistencies between subjective reports and objective autonomic measures emphasize the importance of employing more refined and sensitive assessment tools. Larger and demographically balanced cohorts are required to confirm these results, especially for the underpowered PRKN.
Authors
- Eurípedes Gomes de Carvalho Neto (ORCID: https://orcid.org/0000-0002-5124-7877)
- Nayron Medeiros Soares (ORCID: https://orcid.org/0000-0001-7830-8775)
- Bárbara Maldotti Dalla Corte
- Carlos Roberto de Mello Rieder (ORCID: https://orcid.org/0000-0003-2950-7211)
Institutions
- Universidade Federal do Rio Grande do Sul (BR)
- Universidade Federal de Ciências da Saúde de Porto Alegre (BR)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-08-19
- DOI
- https://doi.org/10.3389/fneur.2025.1657824
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Celgene
- Jazz Pharmaceuticals
- Neurocrine Biosciences
- Verily Life Sciences
- Voyager Therapeutics
- Servier
- H. Lundbeck A/S
- Sun Pharma
- Genentech
- Avid Radiopharmaceuticals